We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Read MoreHide Full Article
Positive news flowed in at Gilead Sciences Inc. (GILD - Free Report) with the European Commission approving the marketing authorization application for Epclusa (Sovaldi 400 mg/velpatasvir 100 mg), the first pan-genotypic, single-tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. The company’s shares inched up 1.3% on the news.
The combination for 12 weeks is approved for the treatment of patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). Epclusa is also the first single-tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for RBV. Physicians will however have the flexibility to consider the addition of RBV for genotype 3 infected patients with compensated cirrhosis.
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this May, which was adopted following an accelerated review procedure.
We note that Epclusa is Gilead’s third sofosbuvir-based treatment to gain approval in the EU for the treatment of chronic HCV infection and is expected to complement Gilead’s current HCV portfolio consisting of Sovaldi and Harvoni.
We remind investors that Epclusa gained FDA approval for the treatment of adults with genotype 1-6 chronic HCV late last month. We are encouraged by the company’s efforts in expanding its HCV franchise. Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor – Merck & Co. Inc.’s (MRK - Free Report) Zepatier.
Meanwhile, Gilead is also evaluating a once-daily fixed-dose combination of Sovaldi/velpatasvir plus GS-9857 (an experimental NS3 protease inhibitor) in phase III studies, for the treatment of chronic genotype 1-6 HCV.
Gilead is a Zacks Rank #2 (Buy) stock. A couple of other favorable stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and Fibrocell Science, Inc. , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead's Pan-Genotypic HCV Drug Epclusa Gains EU Approval
Positive news flowed in at Gilead Sciences Inc. (GILD - Free Report) with the European Commission approving the marketing authorization application for Epclusa (Sovaldi 400 mg/velpatasvir 100 mg), the first pan-genotypic, single-tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. The company’s shares inched up 1.3% on the news.
The combination for 12 weeks is approved for the treatment of patients without cirrhosis or with compensated cirrhosis (Child-Pugh A) and in combination with ribavirin (RBV) for patients with decompensated cirrhosis (Child-Pugh B or C). Epclusa is also the first single-tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for RBV. Physicians will however have the flexibility to consider the addition of RBV for genotype 3 infected patients with compensated cirrhosis.
EU approval was largely expected as the Committee for Medicinal Products for Human Use had issued a favorable opinion this May, which was adopted following an accelerated review procedure.
GILEAD SCIENCES Price
GILEAD SCIENCES Price | GILEAD SCIENCES Quote
We note that Epclusa is Gilead’s third sofosbuvir-based treatment to gain approval in the EU for the treatment of chronic HCV infection and is expected to complement Gilead’s current HCV portfolio consisting of Sovaldi and Harvoni.
We remind investors that Epclusa gained FDA approval for the treatment of adults with genotype 1-6 chronic HCV late last month. We are encouraged by the company’s efforts in expanding its HCV franchise. Competition and pricing pressure have already intensified in the HCV market with the entry of a new competitor – Merck & Co. Inc.’s (MRK - Free Report) Zepatier.
Meanwhile, Gilead is also evaluating a once-daily fixed-dose combination of Sovaldi/velpatasvir plus GS-9857 (an experimental NS3 protease inhibitor) in phase III studies, for the treatment of chronic genotype 1-6 HCV.
Gilead is a Zacks Rank #2 (Buy) stock. A couple of other favorable stocks in the health care sector are Innoviva, Inc. (INVA - Free Report) and Fibrocell Science, Inc. , each sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>